Bio-Rad Laboratories Stock (NYSE:BIO), Analyst Ratings, Price Targets, Predictions

The latest price target for Bio-Rad Laboratories (NYSE: BIO) was reported by Citigroup on April 3, 2024. The analyst firm set a price target for $365.00 expecting BIO to rise to within 12 months (a possible 33.18% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Bio-Rad Laboratories (NYSE: BIO) was provided by Citigroup, and Bio-Rad Laboratories downgraded their neutral rating.

There is no last upgrade for Bio-Rad Laboratories.

The last downgrade for Bio-Rad Laboratories Inc happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on April 3, 2024 so you should expect the next rating to be made available sometime around April 3, 2025.

While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a downgraded with a price target of $400.00 to $365.00. The current price Bio-Rad Laboratories (BIO) is trading at is $274.06, which is out of the analyst’s predicted range.